NCT00040586View on ClinicalTrials.gov

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Prostatic Neoplasms
Interventions
DRUG

Monoclonal Antibody J591

DRUG

Recombinant Interleukin-2

Trial Locations (1)

10021

New York Presbyterian Hospital Medical Oncology/Urology Clinics, New York

Sponsors

Lead Sponsor

BZL Biologics
All Listed Sponsors
lead

BZL Biologics

INDUSTRY